Boehringer Ingelheim International Gmbh

Di Wu

Frank Wu

Michael Robert Turner

Robert Sibley

Ronald John Sorcek

Daniel Richard Marshall

John David Ginn

Anthony S Prokopowicz

Sabine K Schlyer

Erick Richard Roush Young

Xin Guo

Jennifer A Kowalski

Stephen James Boyer

Anthony S Iii Prokopowicz

Sabine Schyler

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

Mineralocorticoid receptor antagonists, of which the following is exemplary. 

Mineralocorticoid receptor antagonists

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Growing community of inventors

Danbury, CT, United States of America

Di Wu